文献速递泌尿男性生殖肿瘤支持与姑息治疗

HLA-A*03与癌症免疫检查点阻断治疗反应:一项流行病学生物标志物研究

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
PubMed 文献 · Lancet Oncol · 2021-12-09

这项流行病学研究在8个队列共3335例接受免疫检查点抑制剂(ICI)治疗和10917例接受非ICI治疗的患者中,发现HLA-A*03等位基因与ICI治疗后总生存期缩短呈加性关联,且在多种ICI药物和瘤种中一致,但在非ICI治疗中未观察到。HLA-A*03纯合子中客观缓解罕见,Meta分析达全基因组显著性且无异质性。

要点

  • HLA-A*03等位基因与ICI治疗后总生存期缩短呈加性关联,MSK-IMPACT队列HR 1.48,DFCI队列HR 1.22。
  • HLA-A*03与ICI治疗后无进展生存期缩短相关,CheckMate肾癌汇总HR 1.31,JAVELIN Renal 101 HR 1.59。
  • HLA-A*03纯合子ICI组客观缓解少见,8例中0例或1例,非携带者分别为26.6%和63.8%。

核心结论

  • HLA-A*03是ICI治疗后反应不佳的预测性生物标志物。
  • 作者认为HLA-A*03值得在随机试验中进一步评估。
  • 作者认为在决定是否启动ICI治疗时可考虑HLA-A*03携带状态。

研究设计与样本

  • 流行病学研究,纳入8个队列:3个观察性队列(MSK-IMPACT、DFCI Profile、The Cancer Genome Atlas)和5项临床试验(JAVELIN Solid Tumour膀胱癌;CheckMate-009、CheckMate-010、CheckMate-025、JAVELIN Renal 101肾细胞癌)。
  • 共纳入3335例接受各类ICI药物(抗PD-1、抗PD-L1、抗CTLA-4抑制剂)治疗的患者和10917例接受非ICI抗癌治疗的患者。
  • 先在MSK-IMPACT发现队列中建模HLA氨基酸变异与总生存期的关联,再详细分析HLA-A*03与临床结局的关联,并在其他队列中重复验证。

主要发现

  • MSK-IMPACT队列中HLA-A*03与ICI治疗后总生存期缩短呈加性关联,每携带一个HLA-A*03等位基因HR 1.48(95%CI 1.20-1.82),p=0.00022。
  • DFCI Profile验证队列中每携带一个HLA-A*03等位基因HR 1.22(95%CI 1.05-1.42),p=0.0097;JAVELIN Solid Tumour膀胱癌试验中HR 1.36(95%CI 1.01-1.85),p=0.047。
  • HLA-A*03效应见于各类ICI药物和瘤种,但在接受替代治疗的患者中未观察到。
  • 三项CheckMate纳武利尤单抗肾细胞癌临床试验汇总人群中,HLA-A*03携带者无进展生存期缩短(HR 1.31,95%CI 1.01-1.71,p=0.044),但在接受对照(依维莫司)治疗者中未观察到。
  • ICI组8例HLA-A*03纯合子中无一例客观缓解,而HLA-A*03非携带者222例中59例(26.6%)、杂合子76例中13例(17.1%)有客观缓解。

关键数值与推荐

  • MSK-IMPACT队列:每HLA-A*03等位基因总生存期HR 1.48(95%CI 1.20-1.82),p=0.00022。
  • DFCI Profile队列:每HLA-A*03等位基因总生存期HR 1.22(95%CI 1.05-1.42),p=0.0097。
  • JAVELIN Solid Tumour膀胱癌试验:每HLA-A*03等位基因总生存期HR 1.36(95%CI 1.01-1.85),p=0.047。
  • 三项CheckMate肾癌试验汇总:HLA-A*03携带者无进展生存期HR 1.31(95%CI 1.01-1.71),p=0.044。
  • JAVELIN Renal 101肾癌ICI组:每HLA-A*03等位基因无进展生存期HR 1.59(95%CI 1.16-2.16),p=0.0036。

临床怎么用

  • 作者认为在决定是否启动ICI治疗时可考虑HLA-A*03携带状态。
  • 作者认为HLA-A*03值得在随机试验中进一步评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy. METHODS: In this epidemiological study, we investigated the clinical outcomes (overall survival, progression free survival, and objective response rate) after treatment for advanced cancer in eight cohorts of patients: three observational cohorts of patients with various types of advanced tumours (the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT] cohort, the Dana-Farber Cancer Institute [DFCI] Profile cohort, and The Cancer Genome Atlas) and five clinical trials of patients with advanced bladder cancer (JAVELIN Solid Tumour) or renal cell carcinoma (CheckMate-009, CheckMate-010, CheckMate-025, and JAVELIN Renal 101). In total, these cohorts included 3335 patients treated with various ICI agents (anti-PD-1, anti-PD-L1, and anti-CTLA-4 inhibitors) and 10 917 patients treated with non-ICI cancer-directed therapeutic approaches. We initially modelled the association of HLA amino-acid variation with overall survival in the MSK-IMPACT discovery cohort, followed by a detailed analysis of the association between HLA-A*03 and clinical outcomes in MSK-IMPACT, with replication in the additional cohorts (two further observational cohorts and five clinical trials). FINDINGS: HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in the MSK-IMPACT cohort (HR 1·48 per HLA-A*03 allele [95% CI 1·20-1·82], p=0·00022), the validation DFCI Profile cohort (HR 1·22 per HLA-A*03 allele, 1·05-1·42; p=0·0097), and in the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01-1·85; p=0·047). The HLA-A*03 effect was observed across ICI agents and tumour types, but not in patients treated with alternative therapies. Patients with HLA-A*03 had shorter progression-free survival in the pooled patient population from the three CheckMate clinical trials of nivolumab for renal cell carcinoma (HR 1·31, 1·01-1·71; p=0·044), but not in those receiving control (everolimus) therapies. Objective responses were observed in none of eight HLA-A*03 homozygotes in the ICI group (compared with 59 [26·6%] of 222 HLA-A*03 non-carriers and 13 (17·1%) of 76 HLA-A*03 heterozygotes). HLA-A*03 was associated with shorter progression-free survival in patients receiving ICI in the JAVELIN Renal 101 randomised clinical trial for renal cell carcinoma (avelumab plus axitinib; HR 1·59 per HLA-A*03 allele, 1·16-2·16; p=0·0036), but not in those receiving control (sunitinib) therapy. Objective responses were recorded in one (12·5%) of eight HLA-A*03 homozygotes in the ICI group (compared with 162 [63·8%] of 254 HLA-A*03 non-carriers and 40 [55·6%] of 72 HLA-A*03 heterozygotes). HLA-A*03 was associated with impaired outcome in meta-analysis of all 3335 patients treated with ICI at genome-wide significance (p=2·01 × 10-8) with no evidence of heterogeneity in effect (I2 0%, 95% CI 0-0·76) INTERPRETATION: HLA-A*03 is a predictive biomarker of poor response to ICI. Further evaluation of HLA-A*03 is warranted in randomised trials. HLA-A*03 carriage could be considered in decisions to initiate ICI in patients with cancer. FUNDING: National Institutes of Health, Merck KGaA, and Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Naranbhai V, Viard M, Dean M, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021. PMID: 34895481. doi:10.1016/S1470-2045(21)00582-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。